CD19 and non-Hodgkin lymphoma: Tong et al. employed TanCAR7, a dual antigen-targeting tandem CAR–T cell therapy against CD19 and CD20, in an open-label, single-arm phase I/2a trial (NCT03097770) to evaluate its efficacy in 33 patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).